Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:18219704rdf:typepubmed:Citationlld:pubmed
pubmed-article:18219704lifeskim:mentionsumls-concept:C0006100lld:lifeskim
pubmed-article:18219704lifeskim:mentionsumls-concept:C0026377lld:lifeskim
pubmed-article:18219704lifeskim:mentionsumls-concept:C0037633lld:lifeskim
pubmed-article:18219704lifeskim:mentionsumls-concept:C1709915lld:lifeskim
pubmed-article:18219704lifeskim:mentionsumls-concept:C0243076lld:lifeskim
pubmed-article:18219704lifeskim:mentionsumls-concept:C1382100lld:lifeskim
pubmed-article:18219704lifeskim:mentionsumls-concept:C0205349lld:lifeskim
pubmed-article:18219704pubmed:issue7lld:pubmed
pubmed-article:18219704pubmed:dateCreated2008-6-30lld:pubmed
pubmed-article:18219704pubmed:abstractTextThe conformations of four BK antagonists, [D-Arg 0, Hyp3, Thi5, D-Phe7, Acc8]BK (1), Aaa[D-Arg 0, Hyp3, Thi5, D-Phe7, Acc8]BK (2), [D-Arg 0, Hyp3, Thi5, 8, Apc7]BK (3), and Aaa[D-Arg(0), Hyp(3), Thi(5, 8), Apc7]BK (4) were studied by using 2D NMR spectroscopy and MD simulations with time-averaged (TAV) restraints. According to the results of the NMR measurements, the BK antagonists contain 7-30% of minor conformation resulting from cis/trans isomerization of the peptide bonds preceding either Pro or Hyp residues. The major conformation of each peptide possesses all peptide bonds in trans configuration. Peptides modified with the Apc residue at position 7 (peptides 3 and 4) possess a higher percentage of minor isomer. Peptide 1 exhibits the strongest vasodepressor potency among the analogs studied and as a single one forms the betaII-turn in the 2-5 fragment, which is believed to be crucial for antagonistic activity. This peptide is also the most compact. The radius of gyration (Rg) amounts to 6.9 A and is by ca 1.5 A lower than that of the remaining analogs. With peptide 4, the ST-turn of type I within the Ser6-Thi8 fragment was found.lld:pubmed
pubmed-article:18219704pubmed:languageenglld:pubmed
pubmed-article:18219704pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18219704pubmed:citationSubsetIMlld:pubmed
pubmed-article:18219704pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18219704pubmed:statusMEDLINElld:pubmed
pubmed-article:18219704pubmed:monthJullld:pubmed
pubmed-article:18219704pubmed:issn1075-2617lld:pubmed
pubmed-article:18219704pubmed:authorpubmed-author:Rodziewicz-Mo...lld:pubmed
pubmed-article:18219704pubmed:authorpubmed-author:SikorskaEmili...lld:pubmed
pubmed-article:18219704pubmed:copyrightInfoCopyright (c) 2008 European Peptide Society and John Wiley & Sons, Ltd.lld:pubmed
pubmed-article:18219704pubmed:issnTypePrintlld:pubmed
pubmed-article:18219704pubmed:volume14lld:pubmed
pubmed-article:18219704pubmed:ownerNLMlld:pubmed
pubmed-article:18219704pubmed:authorsCompleteYlld:pubmed
pubmed-article:18219704pubmed:pagination819-29lld:pubmed
pubmed-article:18219704pubmed:dateRevised2009-11-3lld:pubmed
pubmed-article:18219704pubmed:meshHeadingpubmed-meshheading:18219704...lld:pubmed
pubmed-article:18219704pubmed:meshHeadingpubmed-meshheading:18219704...lld:pubmed
pubmed-article:18219704pubmed:meshHeadingpubmed-meshheading:18219704...lld:pubmed
pubmed-article:18219704pubmed:meshHeadingpubmed-meshheading:18219704...lld:pubmed
pubmed-article:18219704pubmed:meshHeadingpubmed-meshheading:18219704...lld:pubmed
pubmed-article:18219704pubmed:year2008lld:pubmed
pubmed-article:18219704pubmed:articleTitleSolution conformations of bradykinin antagonists modified with Calpha-Calpha cyclized nonaromatic residues.lld:pubmed
pubmed-article:18219704pubmed:affiliationFaculty of Chemistry, University of Gda?sk, Sobieskiego 18, Gda?sk, Poland. milka@chem.univ.gda.pllld:pubmed
pubmed-article:18219704pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:18219704pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed